Pharmaceutical company Aquestive Therapeutics Inc (NASDAQ:AQST) said on Tuesday that it has successfully filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for the investigational product riluzole oral film (ROF) for the treatment of amyotrophic lateral sclerosis (ALS).
The company plans to market the riluzole oral film (ROF) under the brand name Exservan. It added that the goal date for the PDUFA (Prescription Drug User Fee Act) is 30 November 2019.
ROF is a novel formulation of riluzole that is used as an adjunctive therapy in the treatment of amyotrophic lateral sclerosis (ALS). The company is exploring commercial opportunities for ROF in the US and abroad and the candidate received US FDA orphan drug designation in January 2018.
Based on the company's PharmFilm technology, the development of ROF included studies demonstrating its pharmacokinetic bioequivalence to the reference listed drug, Rilutek, as well as additional studies to assess patients' ability to swallow ROF. It can be administered safely and easily, twice daily, without water, fulfilling a critical need for ALS patient.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial